提醒

提醒专业图表

Lantheus Inc. (LNTH)

NasdaqGM: LNTH · 实时价格 · USD

100.95

+0.01 (0.01%)

收盘价： Aug 14, 2026, 3:59 PM

100.95

+0.00%

盘后: 7:34 PM

0.01% (1D)

买价	n/a
市值	6.59B
营收（TTM）	1.56B
净利润（TTM）	275.3M
贝塔值	-0.03
每股收益（TTM）	4.18
市盈率（TTM）	24.15
预期市盈率	16.03
市净率（TTM）	5.42
市销率（TTM）	4.23
Earnings Date	Nov 5, 2026

卖价	n/a
成交量	1,299,906
20日均量	1,309,606
开盘价	100.95
前收盘价	100.94
日内区间	100.85 - 101.10
52周区间	49.67 - 111.86
分析师	Buy
目标价	105 (4.01%)
分红	n/a
除息日	n/a

关于 LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, a...

板块 Healthcare

上市日期 Jun 25, 2015

员工人数 1,193

交易所 NasdaqGM

股票代码 LNTH

官网 https://www.lantheus.com

公司完整简介

财务表现

2025年，Lantheus的营收为1.54B，较上一年的1.53B增长0.5%。净利润为233.56M，下降-25.25%。

财务报表

分析师预测

根据9位分析师的评级，LNTH的平均评级为“Buy”。12个月目标价为105，较最新价格上涨空间4.01%。

股票预测

财报意外

Lantheus 已于 Aug 6, 2026 发布季度财报：

营收为 $388.18M 低于预期 $0, ， 2.68% 同比增长.

每股收益为 1.55 超出预期 0.25, ， -1.27% 同比下滑.

下次财报发布时间

Lantheus Inc. 计划于以下时间发布财报 Nov 5, 2026, 开盘前。
分析师预计营收为 ... 升级

新闻

1周前 · StockStory

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on year to $388.2 million. Its non-GAAP profit of...

1周前 · StockStory

1 Healthcare Stock Worth Your Attention and 2 We Question

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance bu...

1周前 · Simply Wall St.

Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal

Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal was unanimously approved b...

1周前 · Stocktwits

MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading

Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.

1周前 · MT Newswires

Update: Equities Rise Intraday, Oil Slides Amid Middle East Deal Optimism

(Updates with latest market prices and developments.) US stocks climbed intraday as oil prices fe

第 1 页，共 2 页

Lantheus Inc. (LNTH)